Treating CAFs with DNA methyltransferase inhibitors, with ATRA, calcipotriol and minnelide, a prodrug of triptolide, which is an IL-23 inhibitor, restores NF characteristics, reduces markers of inflammation and proliferation, induces quiescence, inhibits cancer invasion by changing the tumor microenvironment composition, and decreases the fibrosis that generates a barrier between the cancer cells and the basement membrane [479,480,481]. Here, NFASC is linked to cancer.